The healthcare community is excited by retatrutide, a new dual GIP and GLP-1 agonist that’s showing remarkable results in preliminary studies . This treatment works by replicating natural hormones to affect appetite and increase feelings of satiety, ultimately leading considerable weight loss . While still under review and not yet available, init